Kornimate/medical-research-clean huggingface dataset:
tranexamic acid in abdominoplasty.

Conditions: Abdominal Wall Defect; Hemorrhage; Bleeding

Summary: the investigators prepared a novel tranexamic acid (txa) study designed to estimate the quantity of blood loss in patients undergoing abdominoplasty surgery. this study aims to quantify blood loss during abdominoplasty with and without txa. the central hypothesis is that txa administration reduces blood loss and fibrinolysis in patients undergoing abdominoplasty surgery.

tranexamic acid (txa) treatment is increasingly emphasized in plastic surgery because txa inhibits fibrinolysis. increased clot stability offers the possibility of preventing blood loss (prevention) and mitigating ongoing hemorrhage. txa therapy has been principally studied in populations; the results of studies in plastic surgery still need to be improved. tranexamic acid is an antifibrinolytic agent that acts as a competitive inhibitor at the lysine binding sites of plasminogen and inhibits the ability of protease plasmin to cleave the fibrin clot. in large randomized controlled trials, it has been reported to be effective in decreasing perioperative blood loss in various circumstances, primarily involving trauma patients. the investigators designed a randomized placebo-controlled trial comparing txa dosing before incision for abdominoplasty. the purpose is to quantify blood loss during plastic surgery with and without txa.

Eligibility criteria:
inclusion criteria: * scheduled abdominoplasty * asa 1 or 2 * age \>18 and \<75 years exclusion criteria: * bmi \ 35 kg/m2 * asa 3 or \> 3 * medical history of thromboembolism * history of hematological disease * treatment with aspirin 14 days before the procedure * treatment with anticoagulants 5 days before the procedure * epilepsy * allergy to tranexamic acid * coagulation disorders
high dose fluconazole in cutaneous leishmaniasis in bahia and manaus

Conditions: Cutaneous Leishmaniasis

Summary: the purpose of this study is to evaluate the therapeutic response to fluconazole in patients with cutaneous leishmaniasis caused by and l.(v.)guyanensis and l.(v.) braziliensis.


Eligibility criteria:
inclusion criteria: * newly diagnosed (untreated) cutaneous leishmaniasis with localized lesions and a positive culture or diagnosed by polymerase chain reaction (pcr) methods or by intradermal skin testing (montenegro test). * number of lesions: 1 to 3 ulcerative lesions. * lesion´s diameter: 1 to 5 cm. * disease duration: up to three months. exclusion criteria: * evidence of serious underlying disease (cardiac, renal, hepatic or pulmonary) * immunodeficiency or antibody to hiv * any non-compensated or uncontrolled condition, such as active tuberculosis, malignant disease, severe malaria, hiv, or other major infectious diseases * lactation, pregnancy (to be determined by adequate test) or inadequate contraception in females of childbearing potential for treatment period plus 2 months * lack of suitability for the trial: * negative parasitology (aspirate/biopsy/pcr)or negative montenegro test * any history of prior anti-leishmania therapy * any condition which compromises ability to comply with the study procedures * administrative reasons: * lack of ability or willingness to give informed consent (patient and/or parent / legal representative) * anticipated non-availability for study visits/procedures

Keywords: fluconazole; meglumine antimoniate;l.braziliensis; l.guyanensis
exercising together: an intervention for prostate cancer survivors and spouses

Conditions: Prostate Cancer

Summary: the purpose of this study is to explore the benefits of "exercising together"-a partnered strength training program for married couples coping with prostate cancer- on the physical and emotional health of prostate cancer survivors and their spouse and on marital quality.


Eligibility criteria:
inclusion criteria for pcs: * received treatment for histologically confirmed prostate cancer * not currently undergoing radiation therapy or chemotherapy for prostate cancer * currently residing with an identifiable spouse willing to participate * 60 years and older at enrollment inclusion criteria for spouses: * currently residing with prostate cancer survivor exclusion criteria for prostate cancer survivor and spouses: * current participation in moderate/vigorous intensity resistance training 2 or more hours per week * cognitive difficulties that preclude answering the survey questions, participating in performance tests, or giving informed consent * medical condition, movement or neurological disorder, or medication that contraindicates participation in resistance exercise * unwillingness to be randomized

Keywords: randomized clinical trial prostate cancer partnered exercise
optimal timing of percutaneous intervention in non-maturing dialysis fistulas

Conditions: Immature Arteriovenous Fistula

Summary: arteriovenous fistulas (avfs) are the preferred type of vascular access for dialysis, but many of them fail to mature. the optimal timing of intervention to salvage immature avfs is unknown.the study proposes a randomized clinical trial comparing the clinical and economic impact of early vs late angioplasty in non-maturing avfs. the study proposes a rct to test the hypothesis that, as compared to early angioplasty of non-maturing avfs, late angioplasty results in a lower proportion of avfs being used at 6 months, but a greater long-term avf patency , lower requirement of subsequent interventions to maintain avf patency for dialysis, and lower overall cost of access maintenance.

the optimal timing of intervention in non-maturing avfs remains controversial, and can only be definitively addressed by a randomized clinical trial (rct) comparing early (6 weeks) vs late (3 months) angioplasty of non-maturing avfs. the investigators will perform a single-center, prospective rct. the investigators will recruit 112 patients who initiated hemodialysis with a cvc, then had a new avf created after commencing dialysis, and then had a 6-week postoperative ultrasound that revealed an immature avf (diameter \< 4 mm diameter or blood flow \< 500 ml/min). these patients will be randomized to one of two groups: an early intervention group that will undergo a routine pta at 6 weeks after avf creation, or a late intervention group in which early pta will be avoided and subsequently be performed only if the 3-month ultrasound indicates persistent avf immaturity. these patients will be followed for 2 years.

Eligibility criteria:
inclusion criteria: * patients with end stage renal disease (esrd). * patients on hemodialysis. * patients using central venous catheter (cvc). * patients who had a new avf created after commencing dialysis. * patients who had immature fistula ( 6-week postoperative ultrasound that revealed an immature avf (diameter \< 4 mm diameter or blood flow \< 500 ml/min). exclusion criteria: • children with age below 18

Keywords: immature avf percutaneous intervention
histopathology images based prediction of molecular pathology in glioma using artificial intelligence

Conditions: Glioma

Summary: this registry aims to collect clinical, molecular and radiologic data including detailed clinical parameters, molecular pathology (1p/19q co-deletion, mgmt methylation, idh and tertp mutations, etc) and images of he slices in primary gliomas. by leveraging artificial intelligence, this registry will seek to construct and refine histopathology image based algorithms that are able to predict molecular pathology or subgroups of gliomas.

non-invasive and precise prediction for molecular biomarkers such as 1p/19q co-deletion, mgmt methylation, idh and tertp mutations is challenging. with the development of artificial intelligence, much more potential lies in the histopathology images of he slices in primary gliomas could be excavated to aid prediction of molecular pathology of gliomas. the creation of a registry for primary glioma with detailed molecular pathology, histopathology image data and with sufficient sample size for deep learning (\>1000) provide considerable opportunities for personalized prediction of molecular pathology with non-invasiveness and precision.

Eligibility criteria:
inclusion criteria: * patients must have radiologically and histologically confirmed diagnosis of primary glioma * life expectancy of greater than 3 months * must receive tumor resection * signed informed consent exclusion criteria: * no gliomas * no sufficient amount of tumor tissues for detection of molecular pathology * patients who are pregnant or breast feeding * patients who are suffered from severe systematic malfunctions

Keywords: molecular histopathology image deep learning machine learning
a study comparing 2 doses of cp-690,550 vs. placebo for the treatment of rheumatoid arthritis in patients on other background arthritis medications

Conditions: Arthritis, Rheumatoid

Summary: this phase 3 study is intended to provide evidence that cp-690,550 dosed 5 mg bid and 10 mg bid is safe and effective when used in combination with a variety of traditional disease modifying antirheumatic drugs in adult patients with rheumatoid arthritis. it is intended to confirm the benefits of cp-690,550 in improving signs and symptoms and physical function that were observed in the phase 2 rheumatoid arthritis studies.


Eligibility criteria:
inclusion criteria: * the patient has a diagnosis of rheumatoid arthritis based on the american college of rheumatology (acr) 1987 revised criteria. * the patient has active disease as defined by both \>=4 tender or painful joints on motion and \>= 4 joints swollen; and either an erythrocyte sedimentation rate (esr) \> 28 mm or a c-reactive protein (crp) concentration \> 7 mg/dl. * patient had an inadequate response to at least one disease modifying antirheumatic drug (traditional or biologic) due to lack of efficacy or toxicity. * patient must remain on at least one background traditional disease modifying antirheumatic drug. * no evidence of inadequately treated latent or active infection with mycobacterium tuberculosis. exclusion criteria: * blood dyscrasias including confirmed: hemoglobin \<9 g/dl or hematocrit \<30%; white blood cell count \<3.0 x 109/l; absolute neutrophil count \<1.2 x 109/l; platelet count \<100 x 109/l. * history of any other rheumatic autoimmune disease other than sjogren's syndrome. * no malignancy or history of malignancy. * history of infection requiring hospitalization, parenteral antimicrobial therapy, or as otherwise judged clinically significant by the investigator, within the 6 months prior to the first dose of study drug.

Keywords: arthritis rheumatoid antirheumatic agents clinical trial
axillary lymph node dissection versus no dissection in breast cancer with positive sentinel lymph node

Conditions: Breast Cancer

Summary: the recently randomized trial (ascog z0011) support that among patients with limited sentinel lymph node (sln) metastatic breast cancer treated with breast conservation and systemic therapy, the use of sentinel lymph node biopsy (slnb) alone compared with axillary lymph node dissection (alnd) did not result in inferior survival. these patients, therefore, are unlikely to benefit from further surgery that results in a longer period of hospitalization, higher costs and higher postoperative morbidity. this result has been written in the 2012 national comprehensive cancer network clinical practice guidelines. however, limitations of z0011, such as failure to achieve target accrual and possible randomization imbalance favoring the slnb-alone group, must be considered. in the other hand, further testing in different country are needed. the investigators design and begin a prospective randomized multicenter phase iii study of alnd vs. no alnd in breast cancer with positive sln--the validation of z0011 in china.

objectives: to determine the effects of complete axillary lymph node dissection (alnd) on survival of patients with sentinel lymph node (sln) metastasis of breast cancer. outline: this is a randomized multicenter study. before randomization, all women were stratified according to age (≤50 years, \>50 years), tumor size(≤2cm, \>2cm) and research center. all the patients underwent lumpectomy and sentinel lymph node biopsy (slnb). eligible women were randomly assigned to alnd or no alnd active comparator: patients undergo axillary lymph node dissection involving removal of at least level i and ii nodes. experimental: no surgery of axillary lymph node in this arm. all the patients were to receive whole-breast opposing tangential-field radiation therapy. the use of adjuvant systemic therapy was determined by the treating physician according to the recently nccn. patients are followed up every 4 months for the first 2 years, every 6 months from the third year to the fifth year, and then annually for a total of 10 years.

Eligibility criteria:
inclusion criteria: * female; * patient aged 18 years and above; * patient with histological proven invasive breast cancer; * clinical t1-t2 disease with no distant metastasis; * patient with clinical n0 status; * patient for whom conservative surgery with sentinel lymph node (sln) technique is feasible from the start in terms of carcinologic; * patient with positive slns 1\~2; * signed consent to participate. exclusion criteria: * history of neoadjuvant chemotherapy or hormone therapy; * history of breast cancer (ipsilateral, i.e. recurrence, or contralateral breast); * history of any other invasive cancer; * initial metastatic disease known; * pregnant women or lactating women; * impossibility to undergo medical examinations of the study for geographical, social or psychological reasons.

Keywords: breast cancer sentinel lymph node biopsy axillary lymph node dissection
study of axitinib in combination with cisplatin and capecitabine in patients with advanced gastric cancer

Conditions: Stomach Neoplasms; Advanced Gastric Cancer

Summary: the purpose of this study is to determine the safe and tolerable dose of axitinib given together with cisplatin and capecitabine in patients with advanced gastric cancer who have not received prior chemotherapy for their advanced cancer.


Eligibility criteria:
inclusion criteria: * confirmed diagnosis of stomach cancer * advanced stomach cancer of stage iv * adequate blood chemistry, blood counts and kidney function * willing to participate to study requirements and sign an informed consent document exclusion criteria: * prior chemotherapy for stomach cancer in its advanced stage * excessive toxicities related to prior therapies * pregnant or breastfeeding patients
non-surgical intervention for carpal tunnel syndrome

Conditions: Carpal Tunnel Syndrome, Susceptibility to

Summary: this randomized controlled trial graduate student research study will explore the effect of non-surgical intervention of the dorsal application of kinesio tape for carpal tunnel syndrome, and forearm wrist hand pain.

this randomized controlled trial graduate student research study will explore the effect of non-surgical intervention of the dorsal application of kinesio tape for carpal tunnel syndrome, and forearm wrist hand pain. little evidence exists for an effective non-surgical intervention. semi-structured interviews will be conducted to explore changes in occupational performance and compliance in order to understand if kinesio tape contributed to results and if so, how the participants perceived the interventions.

Eligibility criteria:
inclusion criteria: * adults \> 18 years of age * fluent in english * report signs and symptoms of carpal tunnel syndrome * pain, numbness, and tingling of the forearm, wrist, or hand, which worsen at night * demonstrate positive phalen's test or tinel's test of the affected extremity exclusion criteria: * currently receiving treatment for carpal tunnel syndrome * history of surgical carpal tunnel release * pregnant * diabetes not controlled by medication * radiculopathy ie: cervical radiculopathy, diabetic radiculopathy * thoracic outlet syndrome * allergy to adhesives or compromised skin integrity * past history of traumatic event, surgery, or congenital impairment of the forearm, wrist, or hand

Keywords: carpal tunnel syndrome, pain, numbness, kinesio tape
effect of isometric handgrip exercises on blood pressure of hypertensive adults

Conditions: Hypertension

Summary: this study is designed to determine the effects of isometric handgrip exercises as compared to aerobic exercises in the hypertensive population, specifically in pre-hypertensives and those with hypertension stage i who are not taking pharmacological treatment. this exercise is designed as part of lifestyle modification for these patients and if proven effective, it can provide an easier to perform exercise regimen as an alternative to be incorporated in the exercise plan of patients who have difficulty in performing aerobic exercises because of musculoskeletal concerns.

hypertension (htn) is a significant public health problem, with an increasing worldwide prevalence. the disease has an impact on reducing the quality of life (qol) and can be life-threatening if not treated early. it is considered the major risk factor for cardiovascular and renal diseases. complications of hypertension can lead to a variety of serious diseases like stroke, heart attack, and even cardiac and renal failure. non-pharmacological management via lifestyle modification is focused in the initial stages of htn through the reduction in alcohol consumption, cessation of tobacco smoking, maintenance of body weight, improvements in nutrition, and increases in physical activity. physical activity improves health status and prevents the complications of hypertension like stroke and heart failure. typically, aerobic exercises in the form of walking and jogging are advised as part of lifestyle modification. effectiveness of resistance training is also worked upon. a relatively newer approach in the form of isometric hand grip exercises (ihg) is also under research because it can serve as a useful alternative for patients who cannot perform aerobic exercises because of musculoskeletal conditions. this study is targeted to assess the effects of ihg exercises, aerobic training, both aerobic and ihg training as well as sham ihg treatment for a comprehensive assessment of effects of ihg training.

Eligibility criteria:
inclusion criteria: * pre-hypertension (systolic bp 120-139 mmhg and diastolic bp\<80) or stage i hypertensive patients (systolic bp 140-159 mmhg and diastolic bp 90-99mm hg. exclusion criteria: * patients who are taking antihypertensive agents * malignant hypertension * physical limitation preventing ihg training (e.g., missing arm, severe hand arthritis, carpal tunnel syndrome, or having a musculoskeletal disorder affecting the upper limb. * active systemic illness that restricts exercise * people doing exercise regularly * any other cardiopulmonary, metabolic, neurological, or psychiatric illness.

Keywords: blood pressure systolic blood pressure diastolic blood pressure isometric handgrip exercises maximal voluntary contraction
eeva™ pregnancy investigational clinical study: a postmarket follow-up study

Conditions: Infertility

Summary: the purpose of this postmarket study is to gather data to evaluate the impact of using eeva with traditional morphology grading on clinical pregnancy rates.

the purpose of this postmarket study is to gather data to evaluate the impact of using eeva with traditional morphology grading on clinical pregnancy rates, as compared to a matched case control group that used morphology grading only to select embryos for transfer.

Eligibility criteria:
inclusion criteria: * women undergoing fresh in vitro fertilization treatment using their own eggs or donor eggs. * ivf cycle attempts ≤ 3. * egg age ≤ 40 years. * planned day 3 embryo transfer. * at least 5 normally fertilized eggs (2pn). * all 2pn embryos must be imaged by eeva. * normal uterine cavity as evaluated by standard methods. * fertilization using only ejaculated sperm (fresh or frozen) - no surgically removed sperm. * willing to comply with study protocol and procedures. * willing to provide written informed consent. exclusion criteria: * planned preimplantation genetic diagnosis. * planned "freeze all" cycle (oocytes or embryos). * concurrent participation in another clinical study.

Keywords: in vitro fertilization assisted reproductive therapy time-lapse image recording image analysis software
randomized assessment of devices used to prevent post-operative hemorrhagic risk in endonasal surgery

Conditions: Otorhinolaryngologic Diseases

Summary: this study evaluates the efficiency and the cost of three medical devices and the abstention of the use of specific product for the post-operative haemostasis in endonasal surgery .

surgiflo® is a matrix of haemostatic frost of porcine protein origin is the coverage of the post-operative bleeding of which one of the indications is in endonasal surgery. floseal® is a haemostatic frost(gel) containing of the thrombin. algosteril® is a lint tent of arginate of calcium.

Eligibility criteria:
inclusion criteria: * endonasal surgery schedule * surgical indications: hypertrophic rhinitis, repeated or chronic infections, extraction of foreign body, polyposes naso-sinusal, benign tumors limited to the nasal pit and in sine, exclusion criteria: * pregnant woman * disorder of the haemostasis known or disrupted preoperative biological balance assessment * use of treatment disrupting the blood coagulation (anti platelet, anti vitamin k, ains) * unchecked hta by the treatment and/or preoperative \> mmhg 160/90 * surgical act including a septoplasty * malignant tumoral surgical indication, or mild overtaking the naso-sinusial system * dacryocystorhinostomy
omega-3 fatty acids in elderly patients with acute myocardial infarction

Conditions: Myocardial Infarction; Heart Failure; Myocardial Revascularization; Atrial Fibrillation

Summary: the aim of the present study is to investigate the possible effects of supplementation with 1.8 g/day of n-3 polyunsaturated fatty acids on cardiovascular morbidity and mortality during a follow-up period of 2 years in an elderly population after having experienced an acute myocardial infarction. the hypothesis is that this supplementation on top of modern therapy will reduce the combined cardiovascular end-point of death, non-fatal myocardial infarction, stroke, revascularizations or hospitalization for new or worsened heart failure with at least 30%.


Eligibility criteria:
inclusion criteria: * patients with acute myocardial infarction discharged from hospital alive exclusion criteria: * being part of another randomized trial * documented intolerance for omega-3 fatty acids * additional disease state that is thought to be incompatible with compliance to the study drugs * additional disease state thought to reduce survival for the follow-up time of 2 years

Keywords: fatty acids, omega-3 aged myocardial infarction